Multiple myeloma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 20, Issue SUPPL. 4, 2009, Pages

  Harousseau, J L ^a   Dreyling, M ^b  

^a HÔTEL DIEU   (France)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN LIGHT CHAIN; IMMUNOGLOBULIN M; LENALIDOMIDE; M PROTEIN; MELPHALAN; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ADVANCED CANCER; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE DISEASE; BONE MARROW BIOPSY; BONE RADIOGRAPHY; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL EVALUATION; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG MEGADOSE; ELDERLY CARE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN ELECTROPHORESIS; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT RESPONSE;

EUROPE; FOLLOW-UP STUDIES; HEALTH PLANNING GUIDELINES; HUMANS; MULTIPLE MYELOMA; SOCIETIES, MEDICAL; TREATMENT OUTCOME;

EID: 66549121706     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp140     Document Type: Article

References (18)

1. The International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders. Br J Haematol 2002; 121: 749-757.
2. Attal M, Harousseau JL. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 91-97.
3. Attal M, Harousseau JL, Facon T et al. Single versus double autologous stem cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495-2502.
4. Attal M, Harousseau JL, Leyvraz S et al. Maintenance therapy with thalidomide improves survival in multiple myeloma patients. Blood 2006; 108: 3289-3294.
5. Barlogie B, Shaughnessy J, Tricot G et al. Treatment of multiple myeloma. Blood 2004; 103: 20-32.
6. Child JA, Morgan GJ, Davies FE et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-1883.
7. Dimopoulos M, Spencer A, Attal M et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357: 2123-2132.
8. Durie BG, Harousseau JL, Miguel JS et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-1473.
9. Facon T, Mary JY, Hulin C et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): A randomized trial. Lancet 2007; 370: 1209-1218.
10. Greipp PR, San Miguel J, Durie BG et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412-3420.
11. Harousseau JL. Role of stem cell transplantation. Hematol Oncol Clin N Am 2007; 21: 1157-1174.
12. Mead GP, Carr-Smith HD, Drayson MT et al. Serum free light chains for monitoring multiple myeloma. Br J Haematol 2004; 126: 348-354.
13. Palumbo A, Bringhen S, Caravita T et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomised controlled trial. Lancet 2006; 367: 825-831.
14. Palumbo A, Facon T, Sonneveld P et al. Thalidomide for multiple myeloma: 10 years later. Blood 2008; 112: 3107-3114.
15. Richardson PG, Sonneveld P, Schuster MW et al. Assessment of proteasome inhibition for extending remissions (APEX) investigators. Bortezomib or high dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-2498.
16. San Miguel JF, Schlag R, Khuageva NK et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359: 906-917.
17. Singhal S, Mehta J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565-1571.
18. Weber DM, Chen C, Nievisky R et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007; 357: 2133-2142.